5-Hydroxy Pyridine Compounds for P2X1 and P2X3 Antagonism

The patent applies parameter changes by modifying the chemical structure of P2X3 receptor antagonists through introducing specific substituents (such as fluorine atoms, chlorine atoms, methyl groups, and various functional groups) at defined positions of the core pyrimidine or purine ring system. These structural parameter changes enhance the biological stability and duration of action of the compounds while maintaining their pain reduction efficacy.

The patent achieves universality by designing P2X3 receptor antagonists with core structures (pyrimidine and purine rings) that can be systematically modified with various substituents to create a series of compounds with enhanced and broadened efficacy. The compounds of Formula 1 and Formula 2 are designed to maintain high affinity for P2X3 receptors while demonstrating improved effectiveness across multiple disease indications including chronic inflammatory pain, neuropathic pain, and platelet aggregation-related disorders.

The patent applies local quality by introducing specific substituents at defined positions of the core pyrimidine or purine ring structure. Rather than randomly complexing the entire molecule, the invention strategically places functional groups (such as fluorine at position 2, chlorine at position 6, methyl groups at positions 1 or 7, and various functional groups at positions 3 or 8) to locally enhance antagonistic activity while maintaining overall structural rationality and synthetic feasibility.